Navigation Links
Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
Date:1/15/2008

of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, there is a risk that the transaction referred to in this press release may be delayed or may not ultimately close if certain conditions set forth in the Step-Up Equity Financing Agreement are not satisfied. You should also review the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Cell Therapeutics, Inc.

Dan Eramian or Susan Callahan

T: 206.272.4343 or 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Cell Therapeutics, Inc.

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)... , TUSTIN, Calif., Dec. 4 /PRNewswire-FirstCal...PPHM ) today announced that it will release its fi...ear 2009 on December 10, 2008 at 7:00 a.m. EST and...s the results at 11:30 a.m. EST on the same day. ...uss financial results for the second quarter ended...
(Date:12/4/2008)... CITY, Dec. 4 /PRNewswire-FirstCall/ - AEterna Zen...iopharmaceutical company focused on endocrine ther...nt and CEO, Juergen Engel, Ph.D., will take part i...ay With Newer And Better Agents" at the upcoming R...ednesday, December 10, 2008 at 4:30 pm (eastern ti...
(Date:12/4/2008)...L, WA, and VANCOUVER, Dec. 4 /PRNewswire-FirstCall... ) will participate on the ,Waging a Battle Agains...althcare Conference on Thursday, December 11 at 8:...ork. During the panel discussion, OncoGenex, Presi...ill provide a brief overview of the company,s onco...
(Date:12/3/2008)... and PHILADELPHIA, Dec. 3 /PRNewswire-FirstCall/ -...day that it is waiving a condition relating to a,... offer to purchase all of,the outstanding shares ...asdaq: GNLB ), for $1.30 per share in cash witho...es. , It is a condition to the completion o...
Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 3
...yless to describe his vision for GE. Specifically,...t-seven-signatures-before-buying-toilet-paper, bur...imbly into markets, execute quickly on decisions, ...o well to tear a note from Welchs playbook. Why? B...fashion. Its time economic developers craft polici...
...e first through the third, will be most interestin...Germany, France, Italy, Britain, Canada and Russia...es. Unfortunately, China is missing from the party...thats a huge mistake! , ,Usually these meetings a...oin hands and smile for the huge group of assemble...
...h Heling, co-founder, SecurePipe, Inc. SecurePip...de variety of industries including manufacturing, ...mer products and technology. Heling discusses inno...ey, and ecruiting a CEO. , , WTN: Please start b...Heling (JH): In 1996, I was doing back-end Unix s...
... Governor Doyle and organized by Forward Wisconsin...echnology industrys leading conference with goals ...capital, showcase the states research and universi... has a growing biotechnology community. According ...jectives in spite of limited conference participat...
Other Biology Technology:Are We Headed for a Global Economic Collapse? 2WTN Exclusive Interview with Josh Heling 2WTN Exclusive Interview with Josh Heling 3On site at BIO 2003 2On site at BIO 2003 3On site at BIO 2003 4On site at BIO 2003 5
(Date:12/3/2008)...uke University study suggests that evolution can b...ogs depend on an energy-efficient style of four-fo...ey, cats seem to have evolved a profoundly ineffic...ird in slow motion. , "It is usually assumed tha...aniel Schmitt, a Duke associate professor of evolu...
(Date:12/3/2008)...lem of children failing to take their medication f...tackled as part of a new university research proje...lists at The University of Nottingham and The Univ...f school children with asthma, diabetes, congenita...rriers that prevent them from taking medicines pre...
(Date:12/3/2008)...mber 3, 2008 Today, the International Society for...rofessional organization of stem cell researchers,...opment of safe and effective stem cell therapies f...the Guidelines for the Clinical Translation of Ste...ember issue of Cell Stem Cell , the official affi...
(Date:12/3/2008)...s that are high in protein and cereal grains produ...e calcium excretion and weaken bones, according to...rine Society,s Journal of Clinical Endocrinology ...asing the alkali content of the diet, with a pill ...s the opposite effect and strengthens skeletal hea...
Breaking Biology News(10 mins):Dogs chase efficiently, but cats skulk counterintuitively 2A spoonful of sugar? 2A spoonful of sugar? 3The International Society for Stem Cell Research releases new guidelines 2The International Society for Stem Cell Research releases new guidelines 3Calcium and vitamin D may not be the only protection against bone loss 2Intercim Launches Pertinence Suite Powered by Velocity 14544 1Intercim Launches Pertinence Suite Powered by Velocity 14544 2Intercim Launches Pertinence Suite Powered by Velocity 14544 3Intercim Launches Pertinence Suite Powered by Velocity 14544 4TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4043 1TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4043 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4043 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4043 4Peapod Offers First Ever Virtual Nutritionist 14537 1Peapod Offers First Ever Virtual Nutritionist 14537 2OPKO Health Announces Issuance of U S Patent Covering the Use and Administration of Certain Anti VEGF siRNAs Including Its Phase III Compound Bevasi 4042 1OPKO Health Announces Issuance of U S Patent Covering the Use and Administration of Certain Anti VEGF siRNAs Including Its Phase III Compound Bevasi 4042 2OPKO Health Announces Issuance of U S Patent Covering the Use and Administration of Certain Anti VEGF siRNAs Including Its Phase III Compound Bevasi 4042 3OPKO Health Announces Issuance of U S Patent Covering the Use and Administration of Certain Anti VEGF siRNAs Including Its Phase III Compound Bevasi 4042 4
...ersity of Wisconsin-Milwaukee, a Wisconsin biotech...found in jellyfish is neuro-protective and may be ..., Testing of aequorin has yielded promising result...ated in Madison. Researcher James Moyer, Jr., an a...n cells to the "lab" equivalent of a stroke, and m...
..."switch gene" in two groups of microscopic plankto...hether certain marine plankton convert a sulfur co...e it can affect the earth,s temperature, or remain... "This new gene offers a powerful tool to study th... sulfur exchange between the ocean and atmosphere,...
...s sack of chemicals and a living cell? It,s all in...biophysical chemist Steven Boxer. With colleagues ...d Lawrence Livermore National Laboratory, he has d...edented resolution-on the order of 100 nanometers,... smaller than entire cells. Understanding the chem...
... the National Cancer Institute, a Wake Forest Univ... to improve the effectiveness of a drug that he d..., Waldemar Debinski, M.D., Ph.D., pioneered a met...BM) with less damage to healthy cells. The drug is...inski is working on its fourth generation in the l...
Other Biology News:UWM brain research supports drug development from jellyfish protein 2Bacterial 'switch gene' regulates how oceans emit sulfur into atmosphere 2With record resolution and sensitivity, tool images how life organizes in a cell membrane 2With record resolution and sensitivity, tool images how life organizes in a cell membrane 3With record resolution and sensitivity, tool images how life organizes in a cell membrane 4With record resolution and sensitivity, tool images how life organizes in a cell membrane 5With record resolution and sensitivity, tool images how life organizes in a cell membrane 6Scientist works to improve treatment for brain tumors 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,518-2) or contact custom
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,517-4) or contact custom
Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /
Biology Products: